|
254
|
Natural killer cell lymphoblastic leukemia/lymphoma
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
253
|
Burkitt's lymphoma (BL) [High miR-17 expression Level]
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
252
|
Burkitt's lymphoma (BL) [MYC chromosomal translocation positive]
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
251
|
Burkitt's lymphoma (BL) [EBV‐positive]
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
250
|
Burkitt's lymphoma (BL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
249
|
T-cell lymphoblastic lymphoma (T-LBL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
248
|
Burkitt's lymphoma (BL) [MYC translocation-negative]
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
247
|
"" Parent
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
246
|
P53-dependent miR induction
|
Neuroblastoma (NB)
|
"" Parent
|
|
245
|
Etoposide Resistance
|
Neuroblastoma (NB)
|
"" Parent
|
|
244
|
MYCN Single Copy
|
Neuroblastoma (NB)
|
"" Parent
|
|
243
|
Silencing hTERT
|
Neuroblastoma (NB)
|
"" Parent
|
|
242
|
Oxidative stress
|
Neuroblastoma (NB)
|
"" Parent
|
|
240
|
Normal MYCN
|
Neuroblastoma (NB)
|
"" Parent
|
|
241
|
Oxygen and Glucose-deprived reoxygenation (OGD/R)
|
Neuroblastoma (NB)
|
"" Parent
|
|
239
|
Negative ALK expression
|
Neuroblastoma (NB)
|
"" Parent
|
|
238
|
MYCN Overexpression
|
Neuroblastoma (NB)
|
"" Parent
|
|
236
|
p53-mutant
|
Neuroblastoma (NB)
|
"" Parent
|
|
237
|
Silencing MYCN
|
Neuroblastoma (NB)
|
"" Parent
|
|
235
|
SLC 34A2 overexpression
|
Neuroblastoma (NB)
|
"" Parent
|
|
234
|
Silencing LncRNA SNHG1
|
Neuroblastoma (NB)
|
"" Parent
|
|
233
|
Silencing CASC11
|
Neuroblastoma (NB)
|
"" Parent
|
|
232
|
silencing LncRNA RMRP
|
Neuroblastoma (NB)
|
"" Parent
|
|
231
|
Silencing LncRNA SNHG7
|
Neuroblastoma (NB)
|
"" Parent
|
|
229
|
Metastasis and Angiogenesis
|
Neuroblastoma (NB)
|
"" Parent
|
|
230
|
Drug Resistance
|
Neuroblastoma (NB)
|
"" Parent
|
|
228
|
Migration
|
Neuroblastoma (NB)
|
"" Parent
|
|
227
|
Migration/Metastasis and Invasion in MYCN amplified cells
|
Neuroblastoma (NB)
|
"" Parent
|
|
225
|
Cisplatin Resistant cells
|
Neuroblastoma (NB)
|
"" Parent
|
|
226
|
BCO1 overexpression
|
Neuroblastoma (NB)
|
"" Parent
|
|
224
|
Migration/Metastasis and Invasion in Non-Amplified MYCN
|
Neuroblastoma (NB)
|
"" Parent
|
|
223
|
Migration & Invasion
|
Neuroblastoma (NB)
|
"" Parent
|
|
221
|
Invasion
|
Neuroblastoma (NB)
|
"" Parent
|
|
222
|
p53-wild type
|
Neuroblastoma (NB)
|
"" Parent
|
|
220
|
Low MYCN level
|
Neuroblastoma (NB)
|
"" Parent
|
|
219
|
1p36 Deletion
|
Neuroblastoma (NB)
|
"" Parent
|
|
218
|
Non-Amplified MYCN (Non-MNA)
|
Neuroblastoma (NB)
|
"" Parent
|
|
217
|
Poor Survival
|
Neuroblastoma (NB)
|
"" Parent
|
|
216
|
MYCN amplified (MNA) and Metastasis
|
Neuroblastoma (NB)
|
"" Parent
|
|
215
|
Well differentiated/ Favorable Histology Low‐Risk group
|
Neuroblastoma (NB)
|
"" Parent
|
|
214
|
Favorable Histology/Low Risk
|
Neuroblastoma (NB)
|
"" Parent
|
|
213
|
Well differentiated/INSS Stages 3,4&4s "advanced stages"
|
Neuroblastoma (NB)
|
"" Parent
|
|
212
|
INSS Stage 3&4 / Advanced primary NB
|
Neuroblastoma (NB)
|
"" Parent
|
|
211
|
Positive ALK expression
|
Neuroblastoma (NB)
|
"" Parent
|
|
210
|
Metastatsis/ INSS Stage 4
|
Neuroblastoma (NB)
|
"" Parent
|
|
209
|
Unfavorable prognostic variables [INSS stage 3,4,4s/ MYCN amplification (MNA)/ Poor Differentiation]
|
Neuroblastoma (NB)
|
"" Parent
|
|
208
|
(miR-516a-5p "high"& miR-487b "low")
|
Neuroblastoma (NB)
|
"" Parent
|
|
207
|
CNS Metastasis
|
Neuroblastoma (NB)
|
"" Parent
|
|
206
|
High risk
|
Neuroblastoma (NB)
|
"" Parent
|
|
205
|
Metastasis
|
Neuroblastoma (NB)
|
"" Parent
|
|
204
|
High Risk (By COG classification)
|
Neuroblastoma (NB)
|
"" Parent
|
|
203
|
High-risk prognostic factors (MYCN amplification/ 11q- deletion/ INSS stage 3 or 4 disease)
|
Neuroblastoma (NB)
|
"" Parent
|
|
202
|
High Risk of Death/Relapse
|
Neuroblastoma (NB)
|
"" Parent
|
|
201
|
Low-risk of death (long Progression-free survival (PFS))
|
Neuroblastoma (NB)
|
"" Parent
|
|
200
|
High-risk of Death
|
Neuroblastoma (NB)
|
"" Parent
|
|
199
|
Hyperdiploidy
|
Neuroblastoma (NB)
|
"" Parent
|
|
198
|
Unfavourable prognostic factors
|
Neuroblastoma (NB)
|
"" Parent
|
|
197
|
MYCN amplified (MNA) and INSS Stage 3& 4 disease
|
Neuroblastoma (NB)
|
"" Parent
|
|
196
|
MYCN amplified (MNA) &/or INSS Stage 4
|
Neuroblastoma (NB)
|
"" Parent
|
|
195
|
MYCN amplified (MNA)
|
Neuroblastoma (NB)
|
"" Parent
|
|
194
|
MYCN amplified (MNA)/ INSS Stage 4
|
Neuroblastoma (NB)
|
"" Parent
|
|
193
|
INSS Stage I
|
Neuroblastoma (NB)
|
"" Parent
|
|
192
|
INSS Stage 4
|
Neuroblastoma (NB)
|
"" Parent
|
|
190
|
Long Survivors
|
Neuroblastoma (NB)
|
"" Parent
|
|
191
|
INSS Stage 4/ Low trk-A expression
|
Neuroblastoma (NB)
|
"" Parent
|
|
189
|
MYCN amplified (MNA) high-risk neuroblastoma
|
Neuroblastoma (NB)
|
"" Parent
|
|
188
|
"" Parent
|
Neuroblastoma (NB)
|
"" Parent
|
|
186
|
Hypoxia
|
Hepatoblastoma
|
"" Parent
|
|
187
|
Endoplasmic Reticulum (ER) stress-induced apoptosis resistance
|
Hepatoblastoma
|
"" Parent
|
|
185
|
hypoxia-induced chemoresistance
|
Hepatoblastoma
|
"" Parent
|
|
184
|
Normoxia
|
Hepatoblastoma
|
"" Parent
|
|
183
|
5-FU resistance
|
Hepatoblastoma
|
"" Parent
|
|
181
|
Migration/Metastasis
|
Hepatoblastoma
|
"" Parent
|
|
182
|
Doxorubicin-resistant
|
Hepatoblastoma
|
"" Parent
|
|
179
|
Migration/Angiogenesis
|
Hepatoblastoma
|
"" Parent
|
|
180
|
Migration and Invasion in HBV +ve cells
|
Hepatoblastoma
|
"" Parent
|
|
178
|
Angiogenesis
|
Hepatoblastoma
|
"" Parent
|
|
177
|
Metastasis/Invasion
|
Hepatoblastoma
|
"" Parent
|
|
176
|
Migration /Metastasis and Invasion
|
Hepatoblastoma
|
"" Parent
|
|
175
|
Invasion
|
Hepatoblastoma
|
"" Parent
|
|
174
|
Migration/Metastasis and Invasion
|
Hepatoblastoma
|
"" Parent
|
|
173
|
Metastasis/Vasculogenic Mimicry (VM) formation
|
Hepatoblastoma
|
"" Parent
|
|
172
|
VEGF-overexpressing cells
|
Hepatoblastoma
|
"" Parent
|
|
171
|
Endoplasmic Reticulum (ER) stress-induced apoptosis resistance (Tunicamycin-treated)
|
Hepatoblastoma
|
"" Parent
|
|
170
|
CD90+ (surface marker of liver cancer stem cells [LCSCs])
|
Hepatoblastoma
|
"" Parent
|
|
169
|
Doxorubicin treated cell (chronic dose)
|
Hepatoblastoma
|
"" Parent
|
|
168
|
circHMGCS1 expressing cells
|
Hepatoblastoma
|
"" Parent
|
|
167
|
Sliencing circHMGCS1
|
Hepatoblastoma
|
"" Parent
|
|
166
|
Silencing LncRNA OIP5-AS1
|
Hepatoblastoma
|
"" Parent
|
|
165
|
Silencing LncRNA LUCAT1
|
Hepatoblastoma
|
"" Parent
|
|
164
|
Silencing LncRNA H19
|
Hepatoblastoma
|
"" Parent
|
|
163
|
Silencing LncRNA NEAT1
|
Hepatoblastoma
|
"" Parent
|
|
162
|
LncRNA TUG-1 Overexpression
|
Hepatoblastoma
|
"" Parent
|
|
161
|
Metastatic HB/Agrresive C2 (gene-based system)/ CHIC High risk group
|
Hepatoblastoma
|
"" Parent
|
|
160
|
High Overall Survival
|
Hepatoblastoma
|
"" Parent
|
|
159
|
Embryonal Subtype
|
Hepatoblastoma
|
"" Parent
|
|
158
|
HBV (+)
|
Hepatoblastoma
|
"" Parent
|
|
157
|
Fetal Sbtype
|
Hepatoblastoma
|
"" Parent
|
|
156
|
Upregulated lncRNA TUG1
|
Hepatoblastoma
|
"" Parent
|
|
155
|
"" Parent
|
Hepatoblastoma
|
"" Parent
|
|
154
|
pediatric-CMLwith bone marrow fibrosis
|
Chronic Myelogenous leukemia (CML)
|
"" Parent
|
|
153
|
"" Parent
|
Chronic Myelogenous leukemia (CML)
|
"" Parent
|
|
152
|
Medulloblastoma with STAT3 phosphorylation
|
Brain Tumor
|
"" Parent
|
|
151
|
Medulloblastoma with SPARC expression
|
Brain Tumor
|
"" Parent
|
|
150
|
Medulloblastoma with P53 mutated
|
Brain Tumor
|
"" Parent
|
|
149
|
Medulloblastoma with MMP-9 overexpression
|
Brain Tumor
|
"" Parent
|
|
148
|
Medulloblastoma with CDK6 positive
|
Brain Tumor
|
"" Parent
|
|
147
|
PNET
|
Brain Tumor
|
"" Parent
|
|
146
|
PNET with Migration/Invasion
|
Brain Tumor
|
"" Parent
|
|
145
|
Medulloblastoma with Migration & Invasion
|
Brain Tumor
|
"" Parent
|
|
144
|
Medulloblastoma with Silencing LncRNA ANRIL
|
Brain Tumor
|
"" Parent
|
|
143
|
NF1-associated Astrocytoma
|
Brain Tumor
|
"" Parent
|
|
142
|
Low Grade Glioma "LGG"
|
Brain Tumor
|
"" Parent
|
|
141
|
Ependymoma
|
Brain Tumor
|
"" Parent
|
|
140
|
Ependymoma (Infratentorial) Grade III
|
Brain Tumor
|
"" Parent
|
|
139
|
INI1(+) AT/RT-like subtype
|
Brain Tumor
|
"" Parent
|
|
138
|
pediatric High Grade Glioma "HGG"
|
Brain Tumor
|
"" Parent
|
|
137
|
High Grade Glioma "HGG"
|
Brain Tumor
|
"" Parent
|
|
136
|
Glioma (Astrocytoma)
|
Brain Tumor
|
"" Parent
|
|
135
|
Pilocytic Astrocytoma and NF1-associated Pilocytic Astrocytoma
|
Brain Tumor
|
"" Parent
|
|
134
|
Diffuse Astrocytoma
|
Brain Tumor
|
"" Parent
|
|
133
|
Glioblastoma (GBM)
|
Brain Tumor
|
"" Parent
|
|
132
|
Spinal Ependymoma (SEPN)
|
Brain Tumor
|
"" Parent
|
|
131
|
Ependymoma (Intracranial) Grade III
|
Brain Tumor
|
"" Parent
|
|
130
|
Ependymoma (Intracranial)
|
Brain Tumor
|
"" Parent
|
|
129
|
Juvenile Pilocytic Astrocytomas
|
Brain Tumor
|
"" Parent
|
|
128
|
Craniopharyngioma
|
Brain Tumor
|
"" Parent
|
|
127
|
Medulloblastoma (Seedling Group)
|
Brain Tumor
|
"" Parent
|
|
126
|
Ependymoma (Relapse/Death)
|
Brain Tumor
|
"" Parent
|
|
125
|
Pilocytic Astrocytoma
|
Brain Tumor
|
"" Parent
|
|
124
|
ATRT
|
Brain Tumor
|
"" Parent
|
|
123
|
Medulloblastoma Grade 3/Medulloblastoma SHH group
|
Brain Tumor
|
"" Parent
|
|
122
|
Glioma (Recurrence)
|
Brain Tumor
|
"" Parent
|
|
121
|
Glioma (Grade IV)
|
Brain Tumor
|
"" Parent
|
|
119
|
Ependymoma (CD44-positive)
|
Brain Tumor
|
"" Parent
|
|
120
|
Medulloblastoma (Molecular subtype Group 4)
|
Brain Tumor
|
"" Parent
|
|
118
|
Brain Stem Glioma
|
Brain Tumor
|
"" Parent
|
|
117
|
Medulloblastoma
|
Brain Tumor
|
"" Parent
|
|
116
|
Medulloblastoma (High risk)
|
Brain Tumor
|
"" Parent
|
|
115
|
Ependymoma (High miR-124-3p)
|
Brain Tumor
|
"" Parent
|
|
114
|
"" Parent
|
Brain Tumor
|
"" Parent
|
|
113
|
homozygous for FLT3-ITD mutation
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
112
|
FLT3 wild type
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
111
|
FLT3-wild type overexpression
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
110
|
silencing LncRNA ANRIL
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
109
|
LncRNA HOTTIP expressed cells
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
108
|
LncRNA NEAT1 Overexpression
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
107
|
Silencing LINC00152
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
106
|
LncRNA HOTAIR Overexpression
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
105
|
Silencing LncRNA MIAT
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
104
|
Silencing circPAN3
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
103
|
MLL-AF4 (KMT2A-AFF1)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
102
|
AML1/ETO positive
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
101
|
Silencing AML1/ETO
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
100
|
Silencing LncRNA TUG1
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
99
|
Silencing LncRNA RPPH1
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
98
|
Non Acute Megakaryoblastic Leukemia with Down syndrome (non-DS-AMKL)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
97
|
Acute Megakaryoblastic Leukemia with Down syndrome (DS-AMKL)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
96
|
MLL rearrangement t(9;11)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
95
|
Silencing LncRNA MALAT1
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
94
|
FLT3-ITD positive
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
93
|
MLL-AF9 knockdown
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
92
|
MLL-rearrangement (MLL-AF9)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
91
|
MLL–AF4 fusion gene postive
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
90
|
Acute promyelocytic leukaemia (APL)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
89
|
Relapsed MLL-rearranged AML
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
88
|
C-Kit mutaion
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
87
|
Non-remission group after the first induction remission therapy
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
86
|
M4-M5 FAB subtype (Monocyte series group)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
85
|
Acute promyelocytic leukaemia (APL) with t(15;17) after therapy in Complete Remission (CR)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
84
|
M3 FAB subtype
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
83
|
M2 FAB subtype
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
82
|
M1 FAB subtype
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
81
|
Acute promyelocytic leukaemia (APL) with t(15;17) at Complete Remission (CR)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
80
|
Acute promyelocytic leukaemia (APL) with t(15;17) / AML with M1, M2, M4, M5, M6 FAB subtypes
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
79
|
Relapsed AML with t(8;21)RUNX1/RUNX1T1
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
78
|
MiR-183-high/PDCD6-low
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
77
|
Diagnosis
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
76
|
GATA1 mutated myeloid leukemia-Down Syndrome (ML-DS) at diagnosis
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
75
|
Myeloid Leukemia-Down Syndrome (ML-DS) at diagnosis
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
74
|
Normal Karyotype-AML (NK-AML) with High miR-155 (Q4).
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
73
|
miR-34b promoter hypermethylation
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
72
|
High EVI1
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
71
|
High Risk group/Flt3-ITD positive/ NPM1 mutation positive
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
70
|
M5b FAB subtype
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
69
|
MLL-rearrangement
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
68
|
t(8;21)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
67
|
t(15;17)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
66
|
FLT3-ITD positive/NPM1 mutated
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
65
|
MLL-rearrangement with t(10;11)
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
64
|
CEBPA mutated
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
63
|
NPM1 mutated/ MLL rearrangement/ FLT3-ITD positive
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
62
|
"" Parent
|
Acute Myeloid Leukemia (AML)
|
"" Parent
|
|
61
|
TLX3-positive HPB-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
60
|
Infant ALL [t(4;11)]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
59
|
Imatinib-resistant cells
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
58
|
ALL[KMT2A-AFF1 gene fusion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
57
|
MLL–ENL fusion gene positive
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
56
|
Glucocorticoid (GC)-resistant ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
55
|
Silencing T leukemia homeobox 3 (TLX3)
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
54
|
TCF3-rearranged BCP-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
53
|
Etoposide-resistant T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
52
|
TAL1-positive T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
51
|
TAL1-negative T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
50
|
MLL–AF4 fusion gene postive
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
49
|
T-ALL with high ST6GALI expression
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
48
|
BCP-ALL with high IL-23 expression
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
47
|
B-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
46
|
HCV‐genotype 4- Associated ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
45
|
BCP-ALL [PAR1 deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
44
|
BCP-ALL [PAX5 deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
43
|
BCP-ALL [IKZF1 deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
42
|
BCP-ALL [MIR31 deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
41
|
BCP-ALL [CDKN2A/B deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
40
|
BCP-ALL [ETV6 deletion]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
39
|
Pre-B ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
38
|
Glucocorticoid (GC)-sensitive ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
37
|
T leukemia homeobox 3 (TLX3)–positive T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
36
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-4747 gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
35
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-320b-1 gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
34
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-922 gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
33
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-200c gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
32
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-1976 gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
31
|
BCP-ALL [ETV6-RUNX1 positive & Hypermethylated miR-320a gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
30
|
BCP-ALL [ETV6-RUNX1 positive]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
29
|
BCP ALL [ERG-related]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
28
|
High HOXA 9&10 cluster genes
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
27
|
[miR-210"low" & CASP8AP2"low"]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
26
|
Methylated miR-124 gene
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
25
|
BCP-ALL [MLL–AF4 positive]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
24
|
Infant ALL [t(4;11)-positive with methylated miRNA gene]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
23
|
T-ALL/MLL rearrangemnet/ BCR-ABL positive
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
22
|
T-ALL [Relapse]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
21
|
t(4;11)
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
20
|
BCP-ALL [ETV6/RUNX1-positive]/ BCP-ALL [No Hyperdiploidy]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
19
|
Hyperdiploidy
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
18
|
E2A-PBX1
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
17
|
E2A-PBX1/T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
16
|
BCP-ALL [ETV6/RUNX1-positive]/T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
15
|
MLL rearrangement
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
14
|
Methylation of miR-9 gene family
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
13
|
Poor Outcome
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
12
|
End of Induction (EOI)
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
11
|
BCP-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
10
|
Relapse
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
9
|
Good Prednisone Response [day 7 treatment]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
8
|
CNS Relapse
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
7
|
BCP-ALL [ETV6/RUNX1-positive]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
6
|
Prednisone-Poor Response (PPR)
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
4
|
T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
5
|
Infant T-ALL
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
3
|
BCP-ALL [High Risk of Relapse]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
2
|
BCP-ALL [t(11;14)(q24.1;q32)]
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
1
|
"" Parent
|
Acute Lymphoblastic Leukemia (ALL)
|
"" Parent
|
|
0
|
"" Parent
|
Parent
|
"" Parent
|
|
255
|
T-cell lymphoblastic leukemia with high Circ-LAMP1
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
256
|
T-cell lymphoblastic lymphoma with high Circ-LAMP1
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
257
|
ALK-positive anaplastic large cell lymphoma (ALCL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
258
|
Diffuse large B-cell lymphoma (DLBCL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
259
|
T-cell Lymphoblastic Leukemia
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
260
|
NK/T-cell lymphoma (EBV-negative)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
261
|
NPM-ALK-positive anaplastic large cell lymphoma (ALCL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
262
|
Epstein-Barr virus-positive Burkitt Lymphoma (BL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
263
|
EBV-positive Burkitt lymphoma (BL)
|
Non-Hodgkin lymphoma (NHL)
|
"" Parent
|
|
264
|
"" Parent
|
Osteosarcoma (OS)
|
"" Parent
|
|
265
|
Chemotherapy Resistance
|
Osteosarcoma (OS)
|
"" Parent
|
|
266
|
Silencing circ-NT5C2
|
Osteosarcoma (OS)
|
"" Parent
|
|
267
|
Silencing ADPGK-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
268
|
UCA1 Overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
269
|
High SNHG16 expression
|
Osteosarcoma (OS)
|
"" Parent
|
|
270
|
IL-1β induction
|
Osteosarcoma (OS)
|
"" Parent
|
|
271
|
Silencing CCAT2
|
Osteosarcoma (OS)
|
"" Parent
|
|
272
|
Silencing circMMP9
|
Osteosarcoma (OS)
|
"" Parent
|
|
273
|
Silencing FBXL19-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
274
|
Silencing HuR
|
Osteosarcoma (OS)
|
"" Parent
|
|
275
|
Silencing circ_0000502
|
Osteosarcoma (OS)
|
"" Parent
|
|
276
|
circ_0000502 Overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
277
|
Circ-ITCH overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
278
|
Silencing circRNA_100876
|
Osteosarcoma (OS)
|
"" Parent
|
|
279
|
Silencing LncRNA NEAT1
|
Osteosarcoma (OS)
|
"" Parent
|
|
280
|
Low CD 133
|
Osteosarcoma (OS)
|
"" Parent
|
|
281
|
Silencing lncRNA SNHG16
|
Osteosarcoma (OS)
|
"" Parent
|
|
282
|
Silencing lncRNA HOTAIR
|
Osteosarcoma (OS)
|
"" Parent
|
|
283
|
Silencing LncRNA MALAT1
|
Osteosarcoma (OS)
|
"" Parent
|
|
284
|
Silencing Circular RNA hsa_circ_0001564
|
Osteosarcoma (OS)
|
"" Parent
|
|
285
|
Silencing LncRNA NORAD
|
Osteosarcoma (OS)
|
"" Parent
|
|
286
|
Silencing LncRNA KCNQ1OT1
|
Osteosarcoma (OS)
|
"" Parent
|
|
287
|
rs1056628 (A/A) in MMP9 gene
|
Osteosarcoma (OS)
|
"" Parent
|
|
288
|
CTGF Overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
289
|
Silencing LncRNA HOXA-AS2
|
Osteosarcoma (OS)
|
"" Parent
|
|
290
|
Silencing LncRNA SNHG5
|
Osteosarcoma (OS)
|
"" Parent
|
|
291
|
Silencing CircRNA Circ_0001658
|
Osteosarcoma (OS)
|
"" Parent
|
|
292
|
MTX-resistant
|
Osteosarcoma (OS)
|
"" Parent
|
|
293
|
Silencing LncRNA ROR
|
Osteosarcoma (OS)
|
"" Parent
|
|
294
|
Silencing Circular RNA circNASP
|
Osteosarcoma (OS)
|
"" Parent
|
|
295
|
Silencing LncRNA LINC00858
|
Osteosarcoma (OS)
|
"" Parent
|
|
296
|
Silencing LncRNA FEZF1-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
297
|
Silencing LncRNA XIST
|
Osteosarcoma (OS)
|
"" Parent
|
|
298
|
Silencing LncRNA TP73-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
299
|
Silencing LncRNA PVT1
|
Osteosarcoma (OS)
|
"" Parent
|
|
300
|
Silencing LncRNA SNHG12
|
Osteosarcoma (OS)
|
"" Parent
|
|
301
|
OS treated with Cisplatin
|
Osteosarcoma (OS)
|
"" Parent
|
|
302
|
Silencing LncRNA LINC00963
|
Osteosarcoma (OS)
|
"" Parent
|
|
303
|
Silencing LncRNA MYOSLID
|
Osteosarcoma (OS)
|
"" Parent
|
|
304
|
High metastasis (High invasion/migration)
|
Osteosarcoma (OS)
|
"" Parent
|
|
305
|
Low Metastasis (Low invasion/migration)
|
Osteosarcoma (OS)
|
"" Parent
|
|
306
|
Silencing LncRNA ODRUL
|
Osteosarcoma (OS)
|
"" Parent
|
|
307
|
LncRNA GAS5 Overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
308
|
Silencing LncRNA FER1L4
|
Osteosarcoma (OS)
|
"" Parent
|
|
309
|
Cisplatin Resistant cells
|
Osteosarcoma (OS)
|
"" Parent
|
|
310
|
Silencing circ_0001721
|
Osteosarcoma (OS)
|
"" Parent
|
|
311
|
Silencing circ_0001721
|
Osteosarcoma (OS)
|
"" Parent
|
|
312
|
Silencing LncRNA TUG1
|
Osteosarcoma (OS)
|
"" Parent
|
|
313
|
Silencing LncRNA LINC01133
|
Osteosarcoma (OS)
|
"" Parent
|
|
314
|
Silencing AFAP1-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
315
|
Silencing LncRNA MIAT
|
Osteosarcoma (OS)
|
"" Parent
|
|
316
|
Metastasis
|
Osteosarcoma (OS)
|
"" Parent
|
|
317
|
Silencing LncRNA AWPPH
|
Osteosarcoma (OS)
|
"" Parent
|
|
318
|
Tumor dormancy-associated miRNAs
|
Osteosarcoma (OS)
|
"" Parent
|
|
319
|
p53+/+
|
Osteosarcoma (OS)
|
"" Parent
|
|
320
|
p53-/-
|
Osteosarcoma (OS)
|
"" Parent
|
|
321
|
Silencing LncRNA miR210HG
|
Osteosarcoma (OS)
|
"" Parent
|
|
322
|
Silencing LncRNA DLX6‐AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
323
|
LncRNA XIST overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
324
|
Doxorubicin-resistant
|
Osteosarcoma (OS)
|
"" Parent
|
|
325
|
Silencing LncRNA HIF1A-AS2
|
Osteosarcoma (OS)
|
"" Parent
|
|
326
|
Siliencing Hsa_circ_0051079
|
Osteosarcoma (OS)
|
"" Parent
|
|
327
|
Silencing Hsa_circ_0051079
|
Osteosarcoma (OS)
|
"" Parent
|
|
328
|
OS Stem Cells (cancer stem cells "CSC")
|
Osteosarcoma (OS)
|
"" Parent
|
|
329
|
LncRNA CCAT1 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
330
|
Silencing LncRNA ZFAS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
331
|
Silencing LINC00152
|
Osteosarcoma (OS)
|
"" Parent
|
|
332
|
Silencing LncRNA SNHG3
|
Osteosarcoma (OS)
|
"" Parent
|
|
333
|
LncRNA SNHG3 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
334
|
LncRNA SNHG16 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
335
|
circular RNA hsa_circ_0002052 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
336
|
Silencing CircRNA CDR1as
|
Osteosarcoma (OS)
|
"" Parent
|
|
337
|
LncRNA SNHG4 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
338
|
LncRNA LINC-PINT Overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
339
|
Silencing LncRNA OIP5-AS1
|
Osteosarcoma (OS)
|
"" Parent
|
|
340
|
Silencing Circ_ANKIB1
|
Osteosarcoma (OS)
|
"" Parent
|
|
341
|
Metastasis/invasion
|
Osteosarcoma (OS)
|
"" Parent
|
|
342
|
Migaration/Metastasis and Invasion
|
Osteosarcoma (OS)
|
"" Parent
|
|
343
|
Silencing LncRNA PCAT6
|
Osteosarcoma (OS)
|
"" Parent
|
|
344
|
Nucleotidyl transferase TUT1 overexpression
|
Osteosarcoma (OS)
|
"" Parent
|
|
345
|
Silencing LncRNA SNHG6
|
Osteosarcoma (OS)
|
"" Parent
|
|
346
|
p53-wild type
|
Osteosarcoma (OS)
|
"" Parent
|
|
347
|
Chemotherapy Resistance
|
Osteosarcoma (OS)
|
"" Parent
|
|
348
|
Chemotherapy Resistance
|
Osteosarcoma (OS)
|
"" Parent
|
|
349
|
"" Parent
|
Renal tumor
|
"" Parent
|
|
350
|
Wilm's tumor (WT)
|
Renal tumor
|
"" Parent
|
|
351
|
Nephroblastoma
|
Renal tumor
|
"" Parent
|
|
352
|
Wilm's tumor (WT) High risk pre-treatment/post-treatment
|
Renal tumor
|
"" Parent
|
|
353
|
Wilm's Tumor (WT)/Regressive WT/Blastemal WT
|
Renal tumor
|
"" Parent
|
|
354
|
MLLT1 mutation in Favorable Histology Wilm's Tumor (FHWT)
|
Renal tumor
|
"" Parent
|
|
355
|
Wilm's Tumor (WT)/Blastemal WT
|
Renal tumor
|
"" Parent
|
|
356
|
Wilm's Tumor (WT)/Regressive WT
|
Renal tumor
|
"" Parent
|
|
357
|
"" Parent
|
Retinoblastoma (RB)
|
"" Parent
|
|
358
|
Germ-line RB1 gene mutation
|
Retinoblastoma (RB)
|
"" Parent
|
|
359
|
Silencing LncRNA XIST
|
Retinoblastoma (RB)
|
"" Parent
|
|
360
|
Silencing LncRNA-H19
|
Retinoblastoma (RB)
|
"" Parent
|
|
361
|
Silencing LncRNA DANCR
|
Retinoblastoma (RB)
|
"" Parent
|
|
362
|
Silencing LncRNA PVT1
|
Retinoblastoma (RB)
|
"" Parent
|
|
363
|
Silencing LncRNA CCAT1
|
Retinoblastoma (RB)
|
"" Parent
|
|
364
|
Silencing LncRNA LINC00202
|
Retinoblastoma (RB)
|
"" Parent
|
|
365
|
"" Parent
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
366
|
Alveolar RMS (aRMS) [13q31 amplification]
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
367
|
Embryonal rhabdomyosarcoma (eRMS)
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
368
|
Alveolar Rhabdomyosarcoma (aRMS)
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
369
|
Etoposide Resistance
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
370
|
Alveolar rhabdomyosarcoma (aRMS) with PAX3-FOXO1 fusion gene
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
371
|
Embryonal Rhabdomyosarcoma (eRMS) with TGF-β1-knockdown
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
372
|
Alveolar Rhabdomyosarcoma (aRMS) with t(2;13)(q35;q14) and p53 loss
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
373
|
Alveolar Rhabdomyosarcoma (aRMS) with TGF-β1-knockdown
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
374
|
Fusion-negative RMS (FN-RMS)
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
375
|
Embryonal rhabdomyosarcoma (eRMS) with Smad3/4-mediated TGF-β1 signal pathway-knockdown
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
376
|
Alveolar Rhabdomyosarcoma (aRMS) with Smad3/4-mediated TGF-β1 signal pathway-knockdown
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
377
|
PAX3-FOXO1 over-expression
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
378
|
PAX3-FOXO1-knockdown
|
Rhabdomyosarcoma (RMS)
|
"" Parent
|
|
379
|
"" Parent
|
Juvenile myelomonocytic leukemia (JMML)
|
"" Parent
|
|
380
|
"" Parent
|
Adrenocortical Tumor (ACT)
|
"" Parent
|
|
381
|
"" Parent
|
Ewing Sarcoma (ES)
|
"" Parent
|